Aeglea BioTherapeutics (AGLE) Names Alison Lawton to Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St futures gain on tech rebound, Middle East peace hopes
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil falls 1% as traders digest escalation in US-Iran strikes
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- UBS sees generational semiconductor boom, highlights stock winners
Aeglea BioTherapeutics Appoints Alison Lawton to Board of Directors
December 17, 2020 4:05 PM ESTAUSTIN, Texas, Dec. 17, 2020 /PRNewswire/ --Â Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high burden diseases, today announced the appointment of Alison Lawton to its Board of Directors. Ms. Lawton previously served as president and CEO of Kaleido Biosciences.
"We are pleased to welcome Alison to the Aeglea Board at this pivotal stage of the company's growth. As we move closer to becoming a commercial-ready company, it is important to have a... More
